MariTide is being studied for the treatment of obesity and Type 2 diabetes and demonstrated weight loss at 52 weeks.
On Wednesday, Outlook Therapeutics Inc (OTLK) stock saw a decline, ending the day at $1.7 which represents a decrease of $-3.19 or -65.24% from the prior close of $4.89. The stock opened at $0.98 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback